Lipid Based Systems For Oral Peptides

Summary: Currently, due to permeability, stability, and delivery challenges, the dosing of macromolecules has been traditionally delivered in an intravenous form. Intravenous drug delivery, while able to provide an optimal pharmacokinetic therapeutic profile, presents challenges such as ease of use, dosing frequency, regulatory challenges, costs, and compliance. Catalent, a leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has invested significantly in developing a broad range of complex oral drug delivery technologies, with OptiGel Bio™ technology being one of the most applicable for peptide drug delivery.

Download the File